Sensidose granted reimbursement for Flexilev in Finland
As part of Sensidose's ongoing geographical expansion, the company last autumn applied for reimbursement for Flexilev with the Finnish Pharmaceutical Price Board (Lääkkeiden hintalautakunta). The application has now been granted and the approval is in accordance with the reimbursement in the other Nordic countries."The positive reimbursement decision is an important step in our geographical market expansion. Now we look forward to getting started with sales as soon as possible and giving Finnish Parkinson's disease patients access to Flexilev, says Sensidose CEO Jack Spira. Flexilev is